Complete responses to two different anti-PD1 agents in a metastatic melanoma patient
In the last decade, immune checkpoint inhibitors changed the landscape of metastatic melanoma. However, the optimal duration of treatment and treatment cessation in responders is largely unknown. Herein, we represent a heavily pretreated metastatic melanoma case who had a complete response to pembro...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology pharmacy practice 2020-03, Vol.26 (2), p.496-499 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 499 |
|---|---|
| container_issue | 2 |
| container_start_page | 496 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 26 |
| creator | Kilickap, Saadettin Guven, Deniz C Aktepe, Oktay H Aktas, Burak Y Dizdar, Omer |
| description | In the last decade, immune checkpoint inhibitors changed the landscape of metastatic melanoma. However, the optimal duration of treatment and treatment cessation in responders is largely unknown. Herein, we represent a heavily pretreated metastatic melanoma case who had a complete response to pembrolizumab and also a complete response with nivolumab after progression during drug-free follow-up. We think that reinduction with a different anti-PD1 antibody may be used in patients with metastatic melanoma responders. Clinical trials with prespecified sequential treatment protocols and large real-life data can further delineate this subject. |
| doi_str_mv | 10.1177/1078155219858657 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2250635252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1078155219858657</sage_id><sourcerecordid>2354651589</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-70ad5f701158871ae8a539abffc13e9945ec692a5a902bb2b5cc243b1dca2e473</originalsourceid><addsrcrecordid>eNp1kM1LxDAQxYMo7rp69yQBL16q-eg06VHWT1jQwwreSppOpUvb1CaL-N-bZVcFwdPMML9583iEnHJ2yblSV5wpzQEEzzXoDNQemfJUqYTl4nU_9nGdbPYTcuT9ijGmldCHZCK5gEyl6ZQs564bWgxIR_SD6z16GhwNH45WTV3jiH2gpg9N8nzDqXmLo6dNTw3tMBgfTGhsbFvTu87QIY6ROCYHtWk9nuzqjLzc3S7nD8ni6f5xfr1IrMwgJIqZCmrFOAetFTeoDcjclHVtucQ8TwFtlgsDJmeiLEUJ1opUlryyRmCq5IxcbHWH0b2v0Yeia7zFNrpBt_aFEMAyCQJERM__oCu3HvvorhAS0gyihzxSbEvZ0Xk_Yl0MY9OZ8bPgrNgkXvxNPJ6c7YTXZYfVz8F3xBFItoCP6f1-_VfwC1MYh4s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2354651589</pqid></control><display><type>article</type><title>Complete responses to two different anti-PD1 agents in a metastatic melanoma patient</title><source>SAGE Complete A-Z List</source><creator>Kilickap, Saadettin ; Guven, Deniz C ; Aktepe, Oktay H ; Aktas, Burak Y ; Dizdar, Omer</creator><creatorcontrib>Kilickap, Saadettin ; Guven, Deniz C ; Aktepe, Oktay H ; Aktas, Burak Y ; Dizdar, Omer</creatorcontrib><description>In the last decade, immune checkpoint inhibitors changed the landscape of metastatic melanoma. However, the optimal duration of treatment and treatment cessation in responders is largely unknown. Herein, we represent a heavily pretreated metastatic melanoma case who had a complete response to pembrolizumab and also a complete response with nivolumab after progression during drug-free follow-up. We think that reinduction with a different anti-PD1 antibody may be used in patients with metastatic melanoma responders. Clinical trials with prespecified sequential treatment protocols and large real-life data can further delineate this subject.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/1078155219858657</identifier><identifier>PMID: 31256744</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Clinical trials ; Immune checkpoint inhibitors ; Immunotherapy ; Melanoma ; Metastases ; Metastasis ; Monoclonal antibodies ; Patients ; PD-1 protein ; Pembrolizumab ; Targeted cancer therapy</subject><ispartof>Journal of oncology pharmacy practice, 2020-03, Vol.26 (2), p.496-499</ispartof><rights>The Author(s) 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-70ad5f701158871ae8a539abffc13e9945ec692a5a902bb2b5cc243b1dca2e473</citedby><cites>FETCH-LOGICAL-c365t-70ad5f701158871ae8a539abffc13e9945ec692a5a902bb2b5cc243b1dca2e473</cites><orcidid>0000-0002-6924-9467</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1078155219858657$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1078155219858657$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31256744$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kilickap, Saadettin</creatorcontrib><creatorcontrib>Guven, Deniz C</creatorcontrib><creatorcontrib>Aktepe, Oktay H</creatorcontrib><creatorcontrib>Aktas, Burak Y</creatorcontrib><creatorcontrib>Dizdar, Omer</creatorcontrib><title>Complete responses to two different anti-PD1 agents in a metastatic melanoma patient</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>In the last decade, immune checkpoint inhibitors changed the landscape of metastatic melanoma. However, the optimal duration of treatment and treatment cessation in responders is largely unknown. Herein, we represent a heavily pretreated metastatic melanoma case who had a complete response to pembrolizumab and also a complete response with nivolumab after progression during drug-free follow-up. We think that reinduction with a different anti-PD1 antibody may be used in patients with metastatic melanoma responders. Clinical trials with prespecified sequential treatment protocols and large real-life data can further delineate this subject.</description><subject>Clinical trials</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunotherapy</subject><subject>Melanoma</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>Pembrolizumab</subject><subject>Targeted cancer therapy</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kM1LxDAQxYMo7rp69yQBL16q-eg06VHWT1jQwwreSppOpUvb1CaL-N-bZVcFwdPMML9583iEnHJ2yblSV5wpzQEEzzXoDNQemfJUqYTl4nU_9nGdbPYTcuT9ijGmldCHZCK5gEyl6ZQs564bWgxIR_SD6z16GhwNH45WTV3jiH2gpg9N8nzDqXmLo6dNTw3tMBgfTGhsbFvTu87QIY6ROCYHtWk9nuzqjLzc3S7nD8ni6f5xfr1IrMwgJIqZCmrFOAetFTeoDcjclHVtucQ8TwFtlgsDJmeiLEUJ1opUlryyRmCq5IxcbHWH0b2v0Yeia7zFNrpBt_aFEMAyCQJERM__oCu3HvvorhAS0gyihzxSbEvZ0Xk_Yl0MY9OZ8bPgrNgkXvxNPJ6c7YTXZYfVz8F3xBFItoCP6f1-_VfwC1MYh4s</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Kilickap, Saadettin</creator><creator>Guven, Deniz C</creator><creator>Aktepe, Oktay H</creator><creator>Aktas, Burak Y</creator><creator>Dizdar, Omer</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6924-9467</orcidid></search><sort><creationdate>202003</creationdate><title>Complete responses to two different anti-PD1 agents in a metastatic melanoma patient</title><author>Kilickap, Saadettin ; Guven, Deniz C ; Aktepe, Oktay H ; Aktas, Burak Y ; Dizdar, Omer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-70ad5f701158871ae8a539abffc13e9945ec692a5a902bb2b5cc243b1dca2e473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Clinical trials</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunotherapy</topic><topic>Melanoma</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>Pembrolizumab</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kilickap, Saadettin</creatorcontrib><creatorcontrib>Guven, Deniz C</creatorcontrib><creatorcontrib>Aktepe, Oktay H</creatorcontrib><creatorcontrib>Aktas, Burak Y</creatorcontrib><creatorcontrib>Dizdar, Omer</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kilickap, Saadettin</au><au>Guven, Deniz C</au><au>Aktepe, Oktay H</au><au>Aktas, Burak Y</au><au>Dizdar, Omer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complete responses to two different anti-PD1 agents in a metastatic melanoma patient</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2020-03</date><risdate>2020</risdate><volume>26</volume><issue>2</issue><spage>496</spage><epage>499</epage><pages>496-499</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>In the last decade, immune checkpoint inhibitors changed the landscape of metastatic melanoma. However, the optimal duration of treatment and treatment cessation in responders is largely unknown. Herein, we represent a heavily pretreated metastatic melanoma case who had a complete response to pembrolizumab and also a complete response with nivolumab after progression during drug-free follow-up. We think that reinduction with a different anti-PD1 antibody may be used in patients with metastatic melanoma responders. Clinical trials with prespecified sequential treatment protocols and large real-life data can further delineate this subject.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>31256744</pmid><doi>10.1177/1078155219858657</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-6924-9467</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2020-03, Vol.26 (2), p.496-499 |
| issn | 1078-1552 1477-092X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2250635252 |
| source | SAGE Complete A-Z List |
| subjects | Clinical trials Immune checkpoint inhibitors Immunotherapy Melanoma Metastases Metastasis Monoclonal antibodies Patients PD-1 protein Pembrolizumab Targeted cancer therapy |
| title | Complete responses to two different anti-PD1 agents in a metastatic melanoma patient |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T20%3A47%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complete%20responses%20to%20two%20different%20anti-PD1%20agents%20in%20a%20metastatic%20melanoma%20patient&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Kilickap,%20Saadettin&rft.date=2020-03&rft.volume=26&rft.issue=2&rft.spage=496&rft.epage=499&rft.pages=496-499&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/1078155219858657&rft_dat=%3Cproquest_cross%3E2354651589%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2354651589&rft_id=info:pmid/31256744&rft_sage_id=10.1177_1078155219858657&rfr_iscdi=true |